The Science of SLD and Dysmetabolism

Create Account

Availability

On-Demand

Expires on Apr 01, 2027

Credit Offered

1.5 AMA PRA Category 1 Credits

1.5 Participation Credits

Description
Learning Objectives
Faculty and Disclosures
Accreditation Information

This activity was presented live in March of 2026 with presentations on deep clinical focus on cholestatic liver diseases, identifying real world management challenges, new therapeutic targets, the latest in patient stratification and care design. This session includes the following topics:

The Role of Metabolic Dysfunction and Alcohol in Steatohepatitis
Understanding the Role of Hunger/Satiety and Addiction Centers in SLD
How Did Our Food and Environment Become Obesogenic in the Last Few Decades?
Antenatal MASH and Obesity – The Role of Maternal Health for the Next Generation
Session 5: Q&A

Upon completion of this activity, participants should be able to:

Examine emerging therapeutic strategies in cholestatic and steatotic liver diseases
Explore the metabolic, genetic, and environmental factors driving liver pathogenesis
Assess evolving concepts in MASLD, MetALD, and their clinical implications
Redesign clinical approaches for diagnosis and treatment using biomarker driven strategies
Evaluate the efficacy and limitations of current and experimental treatment pathways
Engage with future-forward topics, including digital pathology and translational research

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.
The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Rotonya M. Carr, MD, FACP, FAASLD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Intercept
Research Grants: Merck
Expert Testimony: McCarter & English, LLP

Ani Kardashian, MD
Nothing to Disclose

Monika Sarkar, MD, FAASLD, MAS
Grant/Research Support: Zydus Pharmaceuticals, GlaxoSmithKline, Gilead
Principal Investigator: Zydus Pharmaceuticals

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.